banner112

product

2020 China New Design Sepray I Series:(Family) - CE Certified S/T Mode Home Care Ventilator For COPD Therapy T1 – Micomme

Short Description:


product detail imgs

Product Detail

Our goods are commonly recognized and reliable by consumers and may satisfy continually developing economic and social needs for Cpap Machine Medical , Cpap Machine For , Sepray Oh-70c , Standing still today and looking into the future, we sincerely welcome customers all over the world to cooperate with us.
2020 China New Design Sepray I Series:(Family) - CE Certified S/T Mode Home Care Ventilator For COPD Therapy T1 – Micomme Detail:

Description

Home Non-invasive ventilation (NIV) with bi-level positive airway pressure (BiPAP) is commonly used to treat patients admitted to hospital with acute hypercapnic respiratory failure (AHRF) secondary to an acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

Home non-invasive ventilation (NIV) adherence for chronic respiratory failure treatment of obesity hypoventilation syndrome (OHS) vs. chronic obstructive lung disease (COPD). OHS and COPD are both common respiratory conditions that can lead to chronic hypercapnic respiratory failure with the need for domiciliary NIV. Variability of NIV practice is a known issue.

 

Application

Chronic Obstructive Pulmonary Disease, it is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time.

Suppress the inflammation in small airways, it is pivotal as the pathological features of bronchial asthma. Progression of airflow limitation is associated with the increase in accumulation of mucus exudates in the lumen and infiltration and a variety of inflammatory cells are present in the airways of patients with COPD.

 

Advantage

Professional brand trusted by more than 3000 hospitals.

Built in ozone module, automatic cleaning, prevent infection.

Intelligent preheating, avoid dry and cold.

CPAP mode, the patient has strong spontaneous breathing, and the ventilator provides the same pressure in both inspiratory and expiratory phases to help the patient open the airway.

S mode, the ventilator is triggered by the patient. IPAP and EPAP are provided, and patients control respiratory rate and I/E ratio and inspiratory time autonomously.

S/T mode, when the respiratory rate is less than the backup BPM, the S mode works. When the respiratory rate is more than the backup BPM, the T mode works.

 

Specifications

Model T1
Mode CPAP S, S/T

Pressure range

(cmH2O)

4-25
Max. Operation Pressure 30 cmH2O
Pressure accuracy ±0.2 cm H2O
Rise time 1-6 levels(S,T,S/T)

COMF

pressure relief

1-3 levels
Humidification 1-5 levels (113 to 185°F/23 to 85°C)
Ramp time 0 to 45 min (5-minute increments)

Data storage

capacity

8G USB disk
Weight 1.72 kg
Mean sound level ≤30 dB

Product detail pictures:

2020 China New Design Sepray I Series:(Family) - CE Certified S/T Mode Home Care Ventilator For COPD Therapy T1 – Micomme detail pictures


Related Product Guide:

We're going to commit ourselves to giving our esteemed buyers using the most enthusiastically considerate solutions for 2020 China New Design Sepray I Series:(Family) - CE Certified S/T Mode Home Care Ventilator For COPD Therapy T1 – Micomme , The product will supply to all over the world, such as: Malawi, Lisbon, US, Excellent quality, competitive price, punctual delivery and dependable service can be guaranteed. For further inquires please do not hesitate to contact us. Thank you - Your support continuously inspires us.
  • Hope that the company could stick to the enterprise spirit of "Quality, Efficiency, Innovation and Integrity", it will be better and better in the future.
    5 Stars By Candance from Bangkok - 2017.10.25 15:53
    Production management mechanism is completed, quality is guaranteed, high credibility and service let the cooperation is easy, perfect!
    5 Stars By David from Chicago - 2018.07.26 16:51
    Write your message here and send it to us